Could CBD help treat schizophrenia symptoms?

A narrative review found emerging evidence that CBD may reduce positive, negative, and cognitive symptoms of schizophrenia with fewer side effects than conventional antipsychotics, and could also help with cannabis cravings in this population.

Dyck, Garrison J B et al.·Schizophrenia bulletin open·2022·Preliminary EvidenceReview
RTHC-03824ReviewPreliminary Evidence2022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Studies suggest CBD may treat multiple symptom domains of schizophrenia: positive symptoms (hallucinations, delusions), negative symptoms (social withdrawal, flat affect), and cognitive deficits. CBD appears to work through mechanisms distinct from THC, including modulation of anandamide, dopamine, glutamate, and GABA signaling. It may also reduce cannabis cravings and withdrawal in patients who use cannabis.

Key Numbers

Review covers positive, negative, and cognitive symptom domains. Discusses CBD as both standalone and adjunctive treatment. Examines multiple molecular mechanisms.

How They Did This

Narrative review of clinical and preclinical literature on CBD for schizophrenia, covering efficacy, safety, dosing, delivery methods, and molecular mechanisms.

Why This Research Matters

While THC can worsen psychosis, CBD appears to have antipsychotic properties without the metabolic and movement side effects common with conventional antipsychotics.

The Bigger Picture

The potential for CBD to treat schizophrenia while also helping patients reduce cannabis use addresses two linked clinical challenges simultaneously.

What This Study Doesn't Tell Us

Limited number of clinical trials specifically in schizophrenia patients. Optimal dosing and treatment duration remain unclear. Long-term safety data is sparse.

Questions This Raises

  • ?What is the optimal CBD dose for schizophrenia?
  • ?Is CBD more effective as monotherapy or adjunctive treatment?
  • ?Would CBD reduce cannabis use in patients who self-medicate?

Trust & Context

Key Stat:
CBD may address all three symptom domains of schizophrenia
Evidence Grade:
Narrative review of limited clinical evidence. Promising but too early for clinical recommendations.
Study Age:
Published in 2022.
Original Title:
Understanding the Potential Benefits of Cannabidiol for Patients With Schizophrenia: A Narrative Review.
Published In:
Schizophrenia bulletin open, 3(1), sgab053 (2022)
Database ID:
RTHC-03824

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

How is CBD different from THC for schizophrenia?

THC can worsen psychosis by activating CB1 receptors, while CBD appears to have antipsychotic effects through different mechanisms, including boosting anandamide levels and modulating dopamine and glutamate signaling.

Could CBD replace current antipsychotic medications?

It's too early to say. The review suggests CBD could be used as adjunctive treatment alongside current medications, potentially with fewer metabolic and movement-related side effects, but more clinical trials are needed.

Read More on RethinkTHC

Cite This Study

RTHC-03824·https://rethinkthc.com/research/RTHC-03824

APA

Dyck, Garrison J B; Maayah, Zaid H; Eurich, Dean T; Dyck, Jason R B. (2022). Understanding the Potential Benefits of Cannabidiol for Patients With Schizophrenia: A Narrative Review.. Schizophrenia bulletin open, 3(1), sgab053. https://doi.org/10.1093/schizbullopen/sgab053

MLA

Dyck, Garrison J B, et al. "Understanding the Potential Benefits of Cannabidiol for Patients With Schizophrenia: A Narrative Review.." Schizophrenia bulletin open, 2022. https://doi.org/10.1093/schizbullopen/sgab053

RethinkTHC

RethinkTHC Research Database. "Understanding the Potential Benefits of Cannabidiol for Pati..." RTHC-03824. Retrieved from https://rethinkthc.com/research/dyck-2022-understanding-the-potential-benefits

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.